Background: Ketamine has been suggested to be efficient in relieving chronic pain. However, there is inconsistency across studies investigating the effect of ketamine for chronic pain management. We aimed to perform a meta-analysis in order to assess the efficacy of this compound during chronic non-cancer pain conditions. Methods: The study consisted in a meta-analysis of clinical trials comparing ketamine to a placebo during chronic non-cancer pain. The primary endpoint of this study was pain relief 4 weeks after the beginning of treatment. Secondary outcomes were: pain relief 1, 2, 8 and 12 weeks after the beginning of treatment and incidence of psychedelic manifestations. Results: Six studies were included in this meta-analysis. Overall, 99 patients received ketamine and 96 received placebo. Ketamine did not decrease pain intensity at 4 weeks (MD (on a 0 to 10 scale) = À1.12 [À2.33, 0.09], GRADE evidence: very low). However, analysing studies with no high-risk bias found ketamine to decrease pain intensity at 4 weeks and increased the level of GRADE evidence to moderate. Trial sequential analysis confirmed the overall result and revealed the lack of power of this meta-analysis. Ketamine also decreased pain intensity at all other evaluated points in time. Ketamine increased the incidence of psychedelic manifestations in comparison to placebo. Conclusion: Results of this meta-analysis found moderate evidence suggesting the efficacy of ketamine during chronic pain. Further studies are warranted to conclude about the effect of ketamine during chronic pain conditions and to determine optimal administration regimes of this agent during this condition. Significance: Ketamine has been found interesting for managing chronic pain. We performed a meta-analysis aiming to confirm those results. Ketamine was found efficient in alleviating pain up to 12 weeks after the beginning of treatment. However, overall evidence favouring the use of this compound was very low.
Introduction
Chronic pain management remains a challenge for physicians (Argoff et al., 2004; Birklein et al., 2015; Finnerup et al., 2015) , particularly as available treatments are only modestly effective in reducing pain. According to a recent meta-analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., 2015) . Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti-epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., 2015) . As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.
Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., 2017) . It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., 2006; Angst and Clark, 2010; Abrishamkar et al., 2012) . Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., 2011; Niesters and Dahan, 2012; Niesters et al., 2014; Colloca et al., 2017) , many articles have been published over the last decade studying the efficacy of ketamine in alleviating both cancer-related and non-cancer pain (Annetta et al., 2005; Bell, 2009; Blonk et al., 2010; Noppers et al., 2010; Birklein et al., 2015; Jonkman et al., 2017) .
Most of those studies have shown promising results (Hocking and Cousins, 2003; Bell, 2009; Blonk et al., 2010; Noppers et al., 2010; Connolly et al., 2015) . However, given the design of many of those studies as cross-over evaluations (Backonja et al., 1994; Graven-Nielsen et al., 2000; Kvarnstr€ om et al., 2003; Lemming et al., 2005; Eichenberger et al., 2008; Bouwense et al., 2011) and the high heterogeneity in both duration and dosage of ketamine used (Carr et al., 2004a,b; Bell, 2009; Blonk et al., 2010; Huge et al., 2010; Birklein et al., 2015) ; little is known about the long-lasting effect of ketamine during chronic pain or about optimal dosage regimes. Moreover, heterogeneity in dosages used and durations of administration make the qualitative interpretation of available data very difficult. We undertook this metaanalysis in order: (1) to explore the long-lasting potential of ketamine in alleviating pain during chronic non-cancer pain, (2) to determine optimal dose regimes for this indication (3) to determine side effects, especially the psychedelic ones, associated with ketamine and (4) to determine if additional studies are needed in order to allow clear recommendations on the use of ketamine during chronic pain conditions.
Material and methods

Bibliographic search and analysis
We conducted this meta-analysis in accordance with the Cochrane Handbook for Systematic Reviews guidelines (Cochrane), PRISMA statements (Liberati et al., 2009 ) and GRADE methodology (Grading of Recommendations Assessment, Development and Evaluation) (Atkins et al., 2004; Guyatt et al., 2008) . Search and statistical methodologies were similar to previous works on other topics previously published (Bellon et al., 2016; Michelet et al., 2016) . There was no pre-published protocol for this meta-analysis.
Literature databases included Pubmed, Embase, Cochrane central register of controlled trials, clinical trials register and open-access journals not indexed in major databases (Directory of Open Access Journals). The following key words associated were used 'ketamine' or 'chronic pain'. In order to obtain a maximum of studies, reviews focusing on ketamine during chronic pain management were also assessed. Meeting abstracts were not included. The most recent search was April 2017.
Articles obtained from queries were independently analysed by four senior physicians and results checked twice. Those with the following criteria were selected: studies performed in adult patients suffering from chronic non-cancer pain, randomized controlled studies, double blinded (indicated in the methodology section), randomization to two or more groups, standardized treatment protocols for all patients, the presence of a placebo group (the control one) and at least a follow-up of 1 week. Crossover studies were excluded in order to eliminate bias, as ketamine has long-term effects. Studies with a control arm involving active treatment were also excluded. Studies with N of 1 methodology were discarded from the analysis because of the risk of bias in side effect occurrence. Finally, studies performed for cancer pain were excluded from analysis given that a previous meta-analysis has explored this specific topic (Bell et al., 2012) .
Readers (two per article) assessed article quality and potential bias using Cochrane collaborative group criteria: randomization, detailed methodological description demonstrating whether intervention allocations could have been foreseen before or during enrolment, double blind status, incomplete data report statements (excluded patients and data), selective reporting (studied outcomes report verified) and additional bias including the clear definition of a main outcome and the method used to calculate the sample size for adequate study power.
Extracted data consisted of: patient ages and weights, chronic pain characteristics (duration of evolution, aetiology of pain, pain treatments during the study), pain intensity before the beginning of the protocol, pain intensity during the follow-up at different points in time (1, 2, 4, 8 and 12 weeks), the proportion of patients exhibiting a 30 to 50% decrease in pain intensity at those time points, ketamine side effects (psychedelic symptoms), dosage, route of administration and duration of treatment.
The primary endpoint of this meta-analysis was pain intensity, expressed on a quantified tool (numerical scales either questionnaires or rating scales), 4 weeks after the beginning of treatment. The timing of the primary outcome was chosen because it allowed investigating a lasting analgesic effect of ketamine during chronic pain together with an increased probability to have sufficient data to perform statistical analyses. Secondary outcomes were: pain intensity at different points in time from the beginning of treatment (depending of studies' designs) and the presence of psychedelic symptoms during treatment defined as the presence of at least one of the following classical symptoms: agitation, delusion, dissociative state, nightmare, hallucination, unusual emotional feelings and dysphoria. Data were also considered when authors mention their relation with the presence of psychedelic symptoms. When studies included more than one ketamine group, statistics were performed with the group randomized to receive the higher dosage of ketamine.
Statistical analysis
Meta-analysis procedures were performed using Review Manager 5 software (RevMan 5.3, The Cochrane Collaboration, Oxford, United Kingdom). Risk ratio (RR) was computed using the MantelHaenszel method when data were analysed as the number of patients per group exhibiting a reduction in pain intensity of 30 to 50% and for the presence of adverse effects. When pain intensity was expressed as continuous values, data were transformed to a 0-to-10 scale and the mean difference (MD) for pain intensity was calculated (on a 0 to 10 scale). However, to provide a potentially clearer analysis reference point, we also used the minimal clinically important difference (MCID) and defined this difference as ≥1 on a 0 to 10 scale (according to the OMERACT group recommendations and previous publications) (Johnston et al., 2013; Busse et al., 2015) . The number needed to treat (NNT) and Number needed to harm (NNH) were calculated either directly for dichotomous data or estimated from the standardized mean difference (not displayed in results) when data were reported as continuous data, according to methodology described by Furukawa (1999; Furukawa and Leucht, 2011; Johnston et al., 2013) .
A second set of analyses using the Trial Sequential Analysis (TSA) (Kulinskaya and Wood, 2014) were performed for both the primary and the secondary outcome concerning the adverse psychedelic effects using the trial sequential method. This method has been found to be more relevant when analysing cumulative heterogeneous results and decreases type I error. TSA provides three important complementary data points when compared to traditional metaanalysis: First, it combines results and provides a cumulated sample size of included trials using an approximate semi-Bayes procedure with an adjusted threshold for statistical significance and adjusted alpha risk in order to decrease type I error. The second information is the effect of previous meta-analysis on overall results. TSA can perform corrections according to studies previously included in previous meta-analyses. Finally, TSA allows the description of further trial requirements, through a procedure known as trial sequential monitoring boundaries. When the cumulative z-scores for the studied outcome crosses the trial sequential monitoring boundary, the level of evidence for the intervention is considered reached and no further trials are needed. TSA also determines the futility area, indicating that no significant result would be found with additional trials. Finally the O'Brien-Fleming approach using the TSA (the number of patients to be included in the meta-analysis to reach the desired level of power) predicts the sample size to be included in future trials in order to achieve the desirable effect (according to current results) with a sufficient statistical power. For the current analyses, information size was computed assuming an alpha risk of 5%, a beta risk of 20%.
Heterogeneity was assessed using I 2 statistics, which describes the percentage of the variability in effect estimates (RR or MD) due to heterogeneity rather than sampling error. According to the Cochrane review guidelines,1 an I 2 > 40% and a p < 0.1 were considered as the threshold for heterogeneity and indicated the need for a random effects.
Subgroup analyses were performed (when at least two studies included the considered outcome) according to: (1) the cumulative dose of ketamine administered at each point in time of follow-up, (2) the duration of ketamine administration and (3) to the type of chronic pain (neuropathic pain, complex regional pain syndrome I and II, persistent postsurgical pain over 3 months, fibromyalgia . . .etc., according to available included literature). Low dose and high dose of ketamine used for subgroup analyses were defined according to the median value of studies' doses at different points of time. However, given this empirical definition, a metaregression analysis (OpenMeta [Analyst] software: The School of Public Health at Brown University, Providence, RI, USA), was performed using cumulative doses of ketamine at each points of time in order to assess the effect of this factor on the reduction in pain intensity. Comparison between subgroups (called the interaction test) consists of determining the heterogeneity by subgroup. The random effect model was also used in case of heterogeneity between studies concerning dose of ketamine and/or duration of administration. In order to correctly assess the effect of ketamine dosage, all data were homogenized in order to be expressed as equivalent IV ketamine (bioavailability of oral ketamine was considered as 20% according to previous publications). Finally, a subgroup analysis of the primary outcome of the meta-analysis excluding studies with suspected high-risk bias was also performed.
A summary of the overall results were analysed using the GRADE methodology (using online GRADEpro software2 ) for the primary study outcome in order to allow clear recommendations concerning the efficacy of ketamine therapy for chronic pain (Atkins et al., 2004; Guyatt et al., 2008; Alonso-Coello et al., 2016a,b) . The evidence from pooled data (expressed as MD or RR) was downgraded from 'high quality' by one level for high-risk bias in included studies, indirectness of evidence, serious inconsistency, imprecision of effect estimates (either because heterogeneity of the use of random statistical model), potential publication bias (if number of included studies allow assessment) and the potential lack of power of analyses. Data from RevMan software were transferred in the GRADEPRO online program.
Publication bias was assessed by Funnel plot. According to the Cochrane collaborative guideline publication bias should be assessed when analysis aggregating at least 10 studies.
Meta-analysis intervention effect results were expressed as RR [95% confidence interval] 
Results
Using the above selection criteria, 1915 articles were identified; of which six were assessed as relevant according to the selection criteria (Mitchell and Fallon, 2002; Vranken et al., 2005; Schwartzman et al., 2009; Sigtermans et al., 2009; Amr, 2010; Rigo et al., 2017) . None of the studies selected for analysis were published in an open-access journal. The details of the selection process are summarized in Fig. 1 and the description of included studies displayed in Table 1 .
Bias was strongly suspected in two studies (Mitchell and Fallon, 2002; Amr, 2010) . They were categorized high-risk of bias in randomization, blinding and 'other risk of bias'. Two studies did not display a primary outcome or did not clearly describe the methodology used to compute the sample size for the primary outcome. Detailed bias risk assessments are presented in the File S1. Finally, two studies (Vranken et al., 2005; Sigtermans et al., 2009 ) did not separate psychedelic symptoms from other side effects -nausea, vomiting and headache. As a consequence, analyses of psychedelic manifestations did not include data from those studies. Data concerning pain relief were expressed as continuous measurements on a 0 to 10 scale in all studies: the visual analogical scale, the numerical rating scale and 'the average pain during the last 24 hours' of the Brief Pain Inventory. As a consequence, statistical analyses were performed using MD for pain intensity. Duration of administration ranged between 1 and 90 days with five studies administering the active treatment during less than 10 days (Mitchell and Fallon, 2002; Vranken et al., 2005; Schwartzman et al., 2009; Sigtermans et al., 2009; Amr, 2010) and one study during 90 days (Rigo et al., 2017) . Accordingly, subgroup analysis concerning the duration of treatment were performed according to these durations.
Ninety-nine patients received ketamine and 96, a placebo. Some patients received premedication before ketamine administration, either midazolam or haloperidol (Table 1) (Mitchell and Fallon, 2002; Schwartzman et al., 2009; Amr, 2010) . In order to assess the effect of this premedication on psychedelic side effects, a subgroup analysis was added for patients treated with and without premedication. Finally, the study performed by Vranken included two ketamine groups (Vranken et al., 2005) . As stated in the method section, the comparison between the higher ketamine dose and the placebo was included in analyses.
No study reported the number of patients per group exhibiting a reduction in pain intensity of 30 to 50% and for the presence of adverse effects. This outcome was not analysed in the current meta-analysis. Two studies (Schwartzman et al., 2009; Sigtermans et al., 2009 ) displayed results as mean AE SEM (standard error of the mean). SEM was transformed to SD (standard deviation) according to the following equation: SD = SEM * N " (N = sample size).
Overall results
Ketamine administration did not decrease pain intensity at 4 weeks after the beginning of ketamine administration (MD À1.12 [À2.33, 0.09], I 2 = 86%, p < 0.001, number of studies = 4: Fig. 2A ). 2 = 0%, p of I 2 = 0.98, number of studies = 4, Fig. 3C ). According to the method described by Furukawa (Furukawa, 1999) , the NNT was <2.9 and <2.6 for all points in time analyses for an estimated decrease in 50% and 30% of pain intensity in the ketamine group, respectively (Furukawa, 1999; Furukawa and Leucht, 2011; Johnston et al., 2013) . For psychedelic side effects, the NNH was 3 [95% confidence interval 2.2 to 4.5].
Trial sequential analyses
TSA for the primary outcome (Fig. 4A) found ketamine ineffective on pain intensity: the z-curve did not cross the trial sequential monitoring boundary. However, given the informative size of 339 patients, this meta-analysis appears as underpowered to analyse this outcome given that overall 145 patients were included in this analysis.
The same analysis also confirmed the presence of a statistically significant difference between ketamine and placebo on the incidence of psychedelic complications as displayed in Fig. 4B (the z-line crossed the two-sided error target). In addition, the z-curve did not cross the futility region but crossed the trial sequential monitoring boundary; the informative size based on O'Brien-Fleming approach (number of patients to be included in the meta-analysis in order to reach the desired level of significance and power) was 90, while 176 patients were already included in this analysis. Altogether, these results indicate that additional studies are unlikely to change these results.
Finally, given that our meta-analysis was the first performed on this specific topic, no correction for the alpha risk was needed for the TSA.
Study bias analyses
When studies at high risk for bias ((Amr, 2010) File S1) were excluded from the analysis of the primary outcome of the study, the following results were obtained: (1) ketamine was found to decrease pain intensity 4 weeks after the beginning of treatment (MD = À1.73 [À2.39, À1.07], I 2 = 0%, p of I 2 = 0.88, number of studies = 3) and (2) heterogeneity of results decreased. Removing from the Figure 2 (A) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on pain intensity 4 weeks after the beginning of treatment. The square in front of each study (first author and year of publication) is the standardized mean difference (MD) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI). The diamond (black in the figure) is the pooled MD with the 95% confidence interval (CI). (B) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on pain intensity 1 week after the beginning of treatment. The square in front of each study (first author and year of publication) is the standardized mean difference (MD) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI). The diamond (black in the figure) is the pooled MD with the 95% confidence interval (CI). (C) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on pain intensity 2 weeks after the beginning of treatment. The square in front of each study (first author and year of publication) is the standardized mean difference (MD) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI). The diamond (black in the figure) is the pooled MD with the 95% confidence interval (CI). Figure 3 (A) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on pain intensity 8 weeks after the beginning of treatment. The square in front of each study (first author and year of publication) is the standardized mean difference (MD) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI). The diamond (black in the figure) is the pooled MD with the 95% confidence interval (CI). (B) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on pain intensity 12 weeks after the beginning of treatment. The square in front of each study (first author and year of publication) is the standardized mean difference (MD) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI). The diamond (black in the figure) is the pooled MD with the 95% confidence interval (CI). (C) Forest plot of meta-analysis of the effects of ketamine (vs. placebo) on the occurrence of psychedelic side effects. The square in front of each study (first author and year of publication) is the risk ratio (RR) for individual trials, and the corresponding horizontal line is the 95% confidence interval (CI).
analysis of the outcome psychedelic manifestations, the two studies with high risk of bias (Amr, 2010; Mitchell and Fallon, 2002) did not change results of this outcome (RR = 5.38 [2.47, 11.75], I 2 = 0%, p of I 2 = 0.7, number of studies = 2).
Grade analyses
A GRADE analysis summary is displayed in Table 2 . According to GRADE recommendations, the following adjustments were performed: one level Figure 4 (A) Trial sequential analysis graph for the outcome pain intensity at 4 weeks with monitoring boundaries (x axis: studies effect, Y axis cumulative z-Scores). The curve in the full thick line displays the cumulative z-score, horizontal full lines, the boundaries of significance (results in the region within these boundaries are non-significant). The vertical dotted line, the meta-analysis information size (size of patients to be included in order to show a significant outcome: 339). The dotted curve lines: the upper inward-sloping dotted line represents the trial sequential monitoring boundary and the lower outward-sloping dotted line, the futility region. (B) Trial sequential analysis graph for the outcome psychedelic manifestations with monitoring boundaries (x axis: studies effect, Y axis cumulative z-scores). The curve in the full thick line displays the cumulative z-score, horizontal full lines the boundaries of significance (results in the region within these boundaries are non-significant). The vertical dotted line, the meta-analysis information size (size of patients to be included in order to show a significant outcome: 90). The dotted curve lines: the upper inward-sloping dotted line represents the trial sequential monitoring boundary and the lower outward-sloping dotted line the futility region.
downgrade for studies' potential bias (considered as serious) and one level downgrade for results' imprecision -considered as serious or very serious because of result heterogeneity and the random effect model used (28, 29, 38, 39, (48) (49) (50) (51) (52) and one level for the lack of power. Overall, the quality of evidence was found to be very low for the primary outcome (MD = À1.12 [À2.33, 0.09], I 2 = 86%, p < 0.001, number of studies = 4, number of studies = 4, GRADE = very low evidence: Table 3 ). However, when excluding studies with high risk from the analysis of the primary outcome, the quality of evidence was found moderate (MD = À1.73 [À2.39, À1.07], I 2 = 0%, p of I 2 = 0.88, number of studies = 3, GRADE = moderate evidence: Table 2 ).
Subgroup analyses and metaregression
Concerning the dose of ketamine used, there was a tendency for lower doses of ketamine (relative to median cumulative administered doses) to be less effective in reducing pain at 1, 2, 4 and 8 weeks without any statistical differences between these subgroups (Table 3) . Dosage did not impact the efficacy of ketamine at 12 weeks (Table 3) . When metaregression was performed using the cumulative dose of ketamine as a cofactor, this parameter was not found to be associated with a decrease in pain intensity at any time (r = À0.001, p = 0.064, File S2; r = À0.001, p = 0.067, File S3; r = 0.001, p = 0.57, File S4; r = 0.001, p = 0.59, File S5; r = 0.001, p = 0.53, File S6: at 1, 2, 4, 8 and 12 weeks after the beginning of treatment, respectively). Concerning the type of chronic pain, studies were classified as neuropathic pain or CRPS -there was no study including other chronic pain conditions. Although, no statistical difference was found in ketamine efficacy between these two aetiology of chronic pain, there was a tendency for ketamine to be more effective on CRPS at 2, 4 and 8 weeks after the beginning of treatment (Table 3) . Finally, subgroup analyses according to the duration of administration found short administration periods (≤10 days) (Mitchell and Fallon, 2002; Vranken et al., 2005; Schwartzman et al., 2009; Sigtermans et al., 2009; Amr, 2010) significantly more effective than long ones (90 days: Rigo and collaborators) (Rigo et al., 2017) during the first 2 weeks of treatments (Table 3) . Examining daily doses of ketamine revealed that Rigo and collaborators (Rigo et al., 2017) administered a daily dose of 18 mg of equivalent IV ketamine in comparison to 42 to 480 mg of equivalent IV ketamine in other studies (Mitchell and Fallon, One downgrade because of the heterogeneity of studies and/or statistical heterogeneity of the meta-analysis.
c Publication Bias was detected in studies. 2002; Vranken et al., 2005; Schwartzman et al., 2009; Sigtermans et al., 2009; Amr, 2010) . Interestingly all subgroup analyses resulted in a decrease in statistical heterogeneity (Table 3) . Concerning side effects, there were no statistical differences between subgroup analysis of studies without premedication in comparison to those with premedication (RR = 20.94 [1.09, 402 .47], I 22 = 62%, p of I 2 = 0.1, number of studies = 3 versus RR = 7.14 [1. 15, 44.24] , I 2 = 0%, p of I 2 = 0.91, number of studies = 2, p for comparison between subgroups = 0.54, respectively).
Publication Bias analyses
Given that the number of included studies was <10, no publication bias analysis was performed.
Discussion
The main finding of this meta-analysis can be summarized as follows: ketamine was ineffective in decreasing pain intensity at 4 weeks after the beginning of treatment. The level of evidence associated with this result was very low. However, considering studies without high-risk of bias for this outcome, found an efficacy of ketamine on pain reduction at 4 weeks and a moderate level of evidence, according to GRADE evaluation. Trial sequential analysis found this meta-analysis underpowered to conclude about the primary outcome. There was a significant heterogeneity in ketamine dosages and durations of administration among studies. Apart the duration of administration, neither the cumulative dosage of ketamine nor the aetiology of chronic pain were found to influence overall results. Finally, incidence of psychedelic manifestations was statistically more frequent during ketamine administration.
Analgesic effect of ketamine during chronic pain
Ketamine was ineffective on the primary outcome of the study ( Fig. 2A) , this result was associated with a very low quality of evidence (GRADE classification: Table 2 ). Excluding high-risk bias studies from the analysis of the primary outcome found a significant efficacy of ketamine in decreasing pain intensity at 4 weeks with a moderate level of evidence (GRADE classification: Table 2 ). In addition, subgroup analyses revealed an impact of administration regimen on ketamine efficacy (see below subgroup analyses). Considering this result and the decrease in pain intensity associated with ketamine in all other points in time (secondary efficacy outcomes Figs. 2B and C and 3A and B) , ketamine may be considered as a worthwhile therapeutic option in adult chronic pain patients, as previously suggested (Noppers et al., 2010) . However, ketamine efficacy on pain relief has to be interpreted in the light of all findings of this meta-analysis. The estimated NNT for decreasing pain intensity by 50% (<2.9) was below those previously found for the commonest and most efficacious pharmacological treatments of neuropathic painranging from 3 to 6 for antidepressant and antiepileptic agents (Finnerup et al., 2015) . However, ketamine was used as a second or even third line of treatment in studies included in this analysis: the efficacy of ketamine might reflect the additive effect of treatments rather than the efficacy of ketamine. Moreover, ketamine has only been compared with placebo, which is not relevant in practice. Pain reduction using ketamine exceeded the minimal clinically important difference (defined as 1 point on a 0 to 10 scale) at all points in time. However, this reduction in pain intensity can be insufficient to provide a clinically relevant perceived analgesia. This is supported by some evidences targeting the decrease in pain intensity to ≥2 when pharmacological interventions are considered (Forouzanfar et al., 2003; Olsen et al., 2017) . In addition, given that all upper limits of 95% confidence interval of mean differences in pain intensity were ≥À1 (Table 3, Figs. 2  and 3) , some patients will probably not exhibit the minimal clinically important difference defined in our study (Busse et al., 2015) . Conclusively, the level of evidence of results, the influence of studies' quality on these evidences, the lack of power of this meta-analysis (TSA analysis), the heterogeneity of results, the probable moderate effect of ketamine and the absence of any comparison between ketamine and well-evidenced pharmacological treatments of chronic pain, indicate that further investigations are needed to clarify the analgesic effect of ketamine during chronic pain.
Factors impacting the analgesic effect of ketamine
Administering ketamine at high doses during a short period of time (daily doses of 42 to 480 mg during 1 to 10 days) was more effective than administering this compound at lower doses for longer periods (daily dose of 18 mg during 90 days) (Tables 1 and  3 ). This result might be explained by the insufficient concentration of this compound at site-effect at least during the beginning of treatment. This is highly supported by the pharmacokinetic-pharmacodynamics study performed by Dahan and collaborators (Dahan et al., 2011 ) that found high doses of ketamine (480 mg) administered over 5 days to be efficient on pain relief. Interestingly, no statistical difference in pain intensities were found at 8 to 12 weeks when comparing the administration of low dose of ketamine over 90 days to high doses during short periods (Table 3) . Whether this result indicates a delayed onset of action of ketamine (when administered at low concentration) and/or a specific effect of ketamine on neuropathic pain (this condition was associated with longer administration durations: Table 1 ) remains to be determined.
No statistical difference was found in pain relief induced by ketamine when comparing CRPS and neuropathic pain (Table 3 ) despite the higher dosages of ketamine received by patients with CRPS in comparison to neuropathic patients (a total cumulative equivalent IV ketamine of 1000 to 2400 mg over 5 to 10 days (Schwartzman et al., 2009; Sigtermans et al., 2009) versus 1080 mg over 8 weeks (Rigo et al., 2017) for CRPS and neuropathic pain, respectively: Tables 1 and 3 ). The lack of power might represent an explanation for this result. This is strongly supported by the tendency of ketamine to be more effective on CRPS and the more homogenous result of subgroup analyses. Alternatively, the absence of influence of the aetiology of pain on ketamine efficacy might represent an alternative explanation for this result. Recent research seems to indicate that even when focusing on neuropathic pain of a particular aetiology, the pathophysiology, as evidenced by quantitative sensory testing and electrophysiological investigations, may be heterogonous (Attal and Bouhassira, 2015; Dahan et al., 2015) . Furthermore, the pathophysiology and the pain pattern defined by investigations might predict response to treatments more than the aetiology (Attal and Bouhassira, 2015; Dahan et al., 2015) and neuropathic pain treatments are recommended for various other non-neuropathic pain conditions such as CRPS (Birklein et al., 2015; Oaklander and Horowitz, 2015) , suggesting common pathophysiology (Niesters and Dahan, 2012; Niesters et al., 2014; Aronoff, 2016) . NMDA receptors are widely recognized as being involved in the pathophysiology of chronic pain (Nijs et al., 2011; Azari et al., 2012; Colloca et al., 2017) , and action at these receptors may account for the high efficacy of ketamine as supported by our results. Another important point to consider with regard to the pharmacodynamics of ketamine is its effects on mood. Recent research has suggested antidepressive effects of ketamine (Mathew et al., 2012; Jafarinia et al., 2016; Radvansky et al., 2016; Zhang et al., 2016) . As such, over and above the presumed anti-NMDA effect of ketamine, the observed analgesic effect in our meta-analysis may also in part be due to an antidepressant effect, given the strong and complex relationship between depression and pain sensation (Chopra and Arora, 2014; Romero-Sandoval, 2011) . Furthermore, the efficacy of ketamine on pain intensity might incompletely reflect the true potential of this treatment, given that most studies did not fully explore sub-components of pain such as allodynia or hyperesthesia (Park et al., 1995; Zhang et al., 2016) .
Adverse effects of ketamine
Ketamine was associated with statistically more psychedelic effects in comparison to placebo. Moreover, TSA found similar results and indicate the sufficient individual studies' power for detecting differences in side effects. NNH exhibited by ketamine was in the range of the NNH exhibited by commonest pharmacological of pain (between 3 and 5). However, the absence of any described timing of occurrence of these complications, the frequent use of ketamine as a second or even a third line of treatment and the heterogeneity in dosage and duration of treatment, make any conclusion about the maximal doses of ketamine impossible.
Limitations of the study
Our meta-analysis suffers some limitation. The number of studies and cumulative number of patients are limited. This is clearly illustrated by the result of TSA for the primary outcome and the influence of studies' quality on level of evidences. However, this can also be considered as an interesting result given that the TSA allowed defining the optimal number of patients to be included in future studies in order to ensure adequate power for future studies and metaanalyses. Second, most patients included in individual studies were already treated using various therapeutics. Ketamine was used in most patients as a rescue agent; this might explain the low NNT given that other medication might have participated to the beneficial effect of ketamine. This might have also favoured the heterogeneity and results. In addition, this had to be considered for interpreting this study and the potential use of ketamine in chronic pain conditions. There was a great heterogeneity in indications, administration regimen and duration of treatment. Although, subgroup analyses have been performed in order to understand the potential role of those factors on ketamine effect, the limited number of included studies limits the interpretation of those analyses.
Conclusion
This meta-analysis found moderate evidence favouring the use of ketamine for pain reduction during chronic intractable pain in adult patients not suffering from cancer. However, no clear recommendations can be drawn from the current meta-analysis concerning its indication and dosage. Further studies need to be undertaken to more precisely define target populations, the timing and duration of ketamine administration during chronic pain management, optimal dosage and regimes, and the timing of side effects associated with the administration of ketamine. 
